150 related articles for article (PubMed ID: 14717777)
1. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association.
Cohen AD; Zhou P; Xiao Q; Fleisher M; Kalakonda N; Akhurst T; Chitale DA; Moscowitz C; Dhodapkar MV; Teruya-Feldstein J; Filippa D; Comenzo RL
Br J Haematol; 2004 Feb; 124(3):309-14. PubMed ID: 14717777
[TBL] [Abstract][Full Text] [Related]
2. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation.
Comenzo RL; Wally J; Kica G; Murray J; Ericsson T; Skinner M; Zhang Y
Br J Haematol; 1999 Sep; 106(3):744-51. PubMed ID: 10468868
[TBL] [Abstract][Full Text] [Related]
3. Two distinct syndromes of lymphoma-associated AL amyloidosis: a case series and review of the literature.
Telio D; Bailey D; Chen C; Crump M; Reece D; Kukreti V
Am J Hematol; 2010 Oct; 85(10):805-8. PubMed ID: 20872959
[TBL] [Abstract][Full Text] [Related]
4. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
5. Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al).
Bellavia D; Abraham RS; Pellikka PA; Dispenzieri A; Burnett JC; Al-Zahrani GB; Green TD; Manske MK; Gertz MA; Miller FA; Abraham TP
J Am Soc Echocardiogr; 2011 Apr; 24(4):444-54. PubMed ID: 21315556
[TBL] [Abstract][Full Text] [Related]
6. European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Sachchithanantham S; Roussel M; Palladini G; Klersy C; Mahmood S; Venner CP; Gibbs S; Gillmore J; Lachmann H; Hawkins PN; Jaccard A; Merlini G; Wechalekar AD
J Clin Oncol; 2016 Jun; 34(17):2037-45. PubMed ID: 27114592
[TBL] [Abstract][Full Text] [Related]
7. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy.
Shih WJ; Ghesani N; Hongming Z; Alavi A; Schusper S; Mozley D
Clin Nucl Med; 2002 Feb; 27(2):142-3. PubMed ID: 11786752
[No Abstract] [Full Text] [Related]
8. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
Comenzo RL; Zhang Y; Martinez C; Osman K; Herrera GA
Blood; 2001 Aug; 98(3):714-20. PubMed ID: 11468171
[TBL] [Abstract][Full Text] [Related]
9. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).
Abraham RS; Geyer SM; Price-Troska TL; Allmer C; Kyle RA; Gertz MA; Fonseca R
Blood; 2003 May; 101(10):3801-8. PubMed ID: 12515719
[TBL] [Abstract][Full Text] [Related]
12. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
Hosing C; Saliba RM; Körbling M; Acholonu S; McMannis J; Anderlini P; Giralt S; De Lima M; Okoroji GJ; Couriel DR; Champlin R; Khouri IF; Donato ML
Leuk Lymphoma; 2006 Jul; 47(7):1290-4. PubMed ID: 16923559
[TBL] [Abstract][Full Text] [Related]
13. [Heart transplantation and the subsequent treatment of AL amyloidosis].
Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
[TBL] [Abstract][Full Text] [Related]
14. Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production.
Laeng RH; Altermatt HJ; Scheithauer BW; Zimmermann DR
Cancer; 1998 Jan; 82(2):362-74. PubMed ID: 9445195
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience.
Gmeiner Stopar T; Fettich J; Zver S; Mlinaric-Rascan I; Hojker S; Socan A; Peitl PK; Mather S
Nucl Med Commun; 2008 Dec; 29(12):1059-65. PubMed ID: 18987526
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.
Bienert M; Reisinger I; Srock S; Humplik BI; Reim C; Kroessin T; Avril N; Pezzutto A; Munz DL
Eur J Nucl Med Mol Imaging; 2005 Oct; 32(10):1225-33. PubMed ID: 15937686
[TBL] [Abstract][Full Text] [Related]
17. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
18. [Auto-immune manifestations in Non-Hodgkin's lymphoma].
Jardin F; Lévesque H; Tilly H
Rev Med Interne; 2005 Jul; 26(7):557-71. PubMed ID: 15996570
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.
Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P
Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
